Updated results from the SORAML trial of sorafenib in younger patients with newly diagnosed AML - European Medical Journal

Continue

Updated results from the SORAML trial of sorafenib in younger patients with newly diagnosed AML

Oncology
The randomised, controlled phase 2 SORAML trial showed that the addition of the tyrosine kinase inhibitor, sorafenib, to chemotherapy improved event-free survival and relapse-free survival in younger patients with acute myeloid leukaemia (AML).

Rate this content's potential impact on patient outcomes

Thank you!

Please share some more information on the rating you have given